Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can be effectively treated with a variety of ALK-targeted drugs. After the approval of the first-generation ALK inhibitor crizotinib which achieved better results in ...

Anaplastic lymphoma kinase (ALK) gene rearrangements occur in a small portion of patients with non-small cell lung cancer (NSCLC). These gene rearrangements lead to constitutive activation of the ALK kinase and subsequent ALK driven tumor formation.

2024年7月22日 · The molecular pathogenesis, clinical features, and treatment of NSCLC associated with the ALK fusion oncogene are discussed here. An overview of the treatment of metastatic NSCLC, ALK-positive early NSCLC, and the methods and indications for molecular testing are presented elsewhere.

2023年2月16日 · In this Review, we discuss the molecular underpinnings of acquired resistance to ALK-directed therapy and highlight new treatment approaches aimed at inducing long-term remission in ALK +...

4 天之前 · ALK (anaplastic lymphoma kinase) rearrangements represent the third most predominant driver oncogene in non-small cell lung cancer (NSCLC). Although ALK inhibitors are the tyrosine kinase ...

Second- and third-generation ALK inhibitors (alectinib, brigatinib, and lorlatinib) offer to NSCLC patients a clinically meaningful prolongment of survival with a very good quality of life profile. However, resistances to these agents always occur, with less satisfying options for …

2025年1月7日 · 近年来，精准诊疗理念与靶向治疗药物的推广运用，可谓彻底改写了驱动基因阳性非小细胞肺癌（NSCLC）患者的诊疗格局。 这其中，ALK突变因发生率相对较低且在TKI靶向治疗中获得突出疗效，被誉为“钻石突变”。 在2024年全球肺癌领域学术年会上，NSCLC特别是ALK阳性患者靶向治疗领域成绩斐然，再次为NSCLC的临床诊疗注入了一剂「强心针」。 值此契机，为进一步推动我国NSCLC诊疗水平提升，促进领域快速健康发展。 合力共筑 博愈长生——肿瘤规 …

4 天之前 · ALK (anaplastic lymphoma kinase) rearrangements represent the third most predominant driver oncogene in non-small cell lung cancer (NSCLC). Although ALK inhibitors are the tyrosine kinase inhibitors (TKIs) with the longest survival rates in lung cancer, the complex systemic clinical evaluation and the apoptotic cell death evasion of drug-tolerant persister (DTP) cancer cells may limit their ...

2025年3月11日 · Approximately 4% to 5% of non–small cell lung cancer (NSCLC) cases are positive for anaplastic lymphoma kinase (ALK) mutations. 1 For patients with metastatic ALK-positive NSCLC, the emergence of second- and third-generation ALK tyrosine kinase inhibitors (TKIs) has improved outcomes and transformed treatment. Key components of care include ...

3 天之前 · Panelists discuss how the 5-year follow-up data from the CROWN trial support lorlatinib as a frontline treatment for ALK-positive non–small cell lung cancer NSCLC with brain metastasis. For ...